Nataliya Uboha

Associate Professor

University of Wisconsin-Madison Carbone Cancer Center
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (38)

Summary of treatment de-escalation. Overview of dose de-escalation, number ( n ) of patients at each level, and number of patients experiencing a DLT at each dose level. bid, twice daily; D, day; IV, intravenously; PO, orally; qd, once a day.

Year:

2025

Elimusertib concentrations by toxicity. DLT occurrence and week 1 cumulative elimusertib based on day 2 AUC 0–12 hours by cisplatin dose. Open circles, individual patients; solid dash, geometric mean.

Year:

2025

Purpose: The ataxia telangiectasia and Rad3–related kinase inhibitor elimusertib synergizes with cisplatin preclinically. We evaluated the clinical feasibility of combining elimusertib with cisplatin. Patients and Methods: Patients with advanced solid tumors who had received 2 of prior cisplatin, and for whom cisplatin-based treatment was deemed appropriate, were enrolled according to a standard 3 + 3 design, starting elimusertib at 20 mg orally twice daily on days 2 and 9, with cisplatin 60 mg/m 2 intravenously on day 1 of a 21-day cycle. Primary objectives were the determination of the maximum tolerated dose and safety. Secondary objectives included the assessment of elimusertib pharmacokinetics and preliminary efficacy. Results: Fifteen patients were enrolled. Dose level −2 (elimusertib 20 mg once on day 2 and cisplatin 30 mg/m 2 on days 1 and 8) was deemed the maximum tolerated dose; dose-limiting toxicities (DLT) including creatinine increase, hypokalemia, febrile neutropenia, neutropenia, syncope, and thrombocytopenia, required dose de-escalation. Although the four patients with the highest elimusertib exposure all experienced hematologic DLTs within 1 week, they also received a higher day 1 cisplatin dose, precluding a definitive association of elimusertib exposure with DLT occurrence. Of 10 evaluable patients, one (10%) with clear-cell ovarian cancer had a partial response, whereas five (50%) had stable disease. Conclusions: Cisplatin combined with elimusertib was associated with hematologic toxicity requiring significant dose de-escalation. Elimusertib pharmacokinetics was consistent with prior studies. Only modest activity was observed. Further clinical evaluation of elimusertib plus cisplatin is not warranted. Significance: Preclinical data suggest synergy between cisplatin and the ataxia telangiectasia and Rad3–related inhibitor elimusertib, leading to this phase Ib trial in advanced solid tumors evaluating feasibility. The results do not support further examination of the combination due to DLTs observed in the absence of robust efficacy.

Year:

2025

A, PFS and ( B ) OS in the dose-expansion phase overall (ITT) population; ( C ) PFS and ( D ) OS in patients with low CD73 levels, and ( E ) PFS and ( F ) OS in patients with high CD73 levels. ITT, intent-to-treat; NC, not calculable.

Year:

2024

CONSORT diagram for the dose-expansion phase. “a” denotes arm A1: death ( n = 1); withdrawal by patient ( n = 8); other ( n = 4). Arm A3: death ( n = 1); withdrawal by patient ( n = 2); other ( n = 2). “b” denotes patients could be counted more than once in this category if they discontinued different chemotherapy options for different reasons. “c” denotes as permitted per study protocol, patients from arms A2 and A3 continued to receive immunotherapy off-study after the study closure on July 22, 2022, and patients from all arms continued to receive treatment per standard of care at their site. “d” denotes end of study status as defined in the protocol. “e” denotes “sponsor decision" and includes patients either still on treatment or in survival follow-up at the time of study closure. N , number of patients in each treatment group.

Year:

2024

Purpose: This multicenter phase II basket trial investigated the efficacy, safety, and pharmacokinetics of Debio 1347, an investigational, oral, highly selective, ATP-competitive, small molecule inhibitor of FGFR1–3, in patients with solid tumors harboring a functional FGFR1–3 fusion. Patients and Methods: Eligible adults had a previously treated locally advanced (unresectable) or metastatic biliary tract (cohort 1), urothelial (cohort 2), or another histologic cancer type (cohort 3). Debio 1347 was administered at 80 mg once daily, continuously, in 28-day cycles. The primary endpoint was the objective response rate. Secondary endpoints included duration of response, progression-free survival, overall survival, pharmacokinetics, and incidence of adverse events. Results: Between March 22, 2019, and January 8, 2020, 63 patients were enrolled and treated, 30 in cohort 1, 4 in cohort 2, and 29 in cohort 3. An unplanned preliminary statistical review showed that the efficacy of Debio 1347 was lower than predicted, and the trial was terminated. In total, 3 of 58 evaluable patients had partial responses, representing an objective response rate of 5%, with a further 26 (45%) having stable disease (≥6 weeks duration). Grade ≥3 treatment-related adverse events occurred in 22 (35%) of 63 patients, with the most common being hyperphosphatemia (13%) and stomatitis (5%). Two patients (3%) discontinued treatment due to adverse events. Conclusions: Debio 1347 had manageable toxicity; however, the efficacy in patients with tumors harboring FGFR fusions did not support further clinical evaluation in this setting. Our transcriptomic-based analysis characterized in detail the incidence and nature of FGFR fusions across solid tumors. See related commentary by Hage Chehade et al., p. 4549

Year:

2024

Baseline median variant allelic frequency (VAF) by KRAS status (A), exploratory OS and PFS stratified by baseline median VAF (B) and distribution of KRAS mutation status (C), VAF (D) and blood TMB (E) by arm

Year:

2024

Purpose: Pancreatic ductal adenocarcinoma upregulates CD73, potentially contributing to immune surveillance evasion. Combining oleclumab (CD73 inhibitor) and durvalumab with chemotherapy may identify an effective treatment option. Patients and Methods: We describe a multicenter phase Ib/II randomized clinical trial in patients with metastatic pancreatic ductal adenocarcinoma, untreated (cohort A) or previously received gemcitabine-based chemotherapy (cohort B; NCT03611556). During escalation, patients received oleclumab 1,500 or 3,000 mg, durvalumab 1,500 mg, and gemcitabine plus nab-paclitaxel (GnP; cohort A; n = 14) or modified FOLFOX (cohort B; n = 11). During expansion, cohort A patients ( n = 170) were randomized to GnP (arm A1), oleclumab [recommended phase II dose (RP2D)] with GnP (arm A2), or oleclumab (RP2D) with durvalumab plus GnP (arm A3). Primary objectives were safety (escalation) and objective response rate (expansion). Secondary objectives included progression-free survival (PFS) and overall survival (OS). Results: During escalation, 1/11 patients from cohort B (oleclumab 3,000 mg) experienced two dose-limiting toxicities. Oleclumab’s RP2D was 3,000 mg. During expansion, grade ≥3 treatment-related adverse events occurred in 67.7% (42/62) of patients in A1, 73.7% (28/38) in A2, and 77.1% (54/70) in A3. The objective response rate was 29.0%, 21.1%, and 32.9% in A1, A2, and A3, respectively (A1 vs. A3; P = 0.650). PFS [HR = 0.72; 95% confidence interval (CI), 0.47, 1.11] and OS (HR = 0.75; 95% CI, 0.50–1.13) were similar for A3 versus A1. Patients with high CD73 expression had improved PFS and OS in A3 versus A1, although this should be interpreted with caution. Conclusions: Although the safety profile was acceptable, this study did not meet its primary efficacy endpoint.

Year:

2024

Adagrasib, an irreversible, selective KRAS G12C inhibitor, may be an effective treatment in KRAS G12C -mutated colorectal cancer, particularly when combined with an anti-EGFR antibody. In this analysis of the KRYSTAL-1 trial, patients with previously treated KRAS G12C -mutated unresectable or metastatic colorectal cancer received adagrasib (600 mg twice daily) plus cetuximab. The primary endpoint was objective response rate (ORR) by blinded independent central review. Ninety-four patients received adagrasib plus cetuximab. With a median follow-up of 11.9 months, ORR was 34.0%, disease control rate was 85.1%, and median duration of response was 5.8 months (95% confidence interval [CI], 4.2–7.6). Median progression-free survival was 6.9 months (95% CI, 5.7–7.4) and median overall survival was 15.9 months (95% CI, 11.8–18.8). Treatment-related adverse events (TRAEs) occurred in all patients; grade 3–4 in 27.7% and no grade 5. No TRAEs led to adagrasib discontinuation. Exploratory analyses suggest circulating tumor DNA may identify features of response and acquired resistance. Significance: Adagrasib plus cetuximab demonstrates promising clinical activity and tolerable safety in heavily pretreated patients with unresectable or metastatic KRAS G12C -mutated colorectal cancer. These data support a potential new standard of care and highlight the significance of testing and identification of KRAS G12C mutations in patients with colorectal cancer. This article is featured in Selected Articles from This Issue, p. 897 See co-corresponding author Rona Yaeger discuss this research article, published simultaneously at the AACR Annual Meeting 2024: https://vimeo.com/932606282/f27a6e46f4

Year:

2024

Table S3. Efficacy summary per BICR with adagrasib plus cetuximab in previously treated patients with KRASG12C-mutated unresectable or metastatic CRC, overall, and in phase 1 and phase 2 cohorts.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (33)

Scott E. Kopetz

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Samuel Klempner

Associate Professor

Massachusetts General Hospital

UNITED STATES
View details

Matthew Reilley

Assistant Professor

University of Virginia School of Medicine

UNITED STATES
View details

Mariano Ponz-Sarvise

Universidad de Navarra

SPAIN
View details

Paul Frankel

Research Professor

Beckman Research Institute, City of Hope

UNITED STATES
View details

Wells Messersmith

Professor and Cancer Center Director

University of Colorado Cancer Center

UNITED STATES
View details

Tanios Bekaii-Saab

Mayo Clinic

UNITED STATES
View details

Arjun Mittra

Assistant Professor

The Ohio State University Comprehensive Cancer Center

UNITED STATES
View details

Nancy Chan

Assistant Professor

NYU School of Medicine

UNITED STATES
View details

Niharika Mettu

Duke University

UNITED STATES
View details

Jan Beumer

Professor (PAR)

Johns Hopkins University

UNITED STATES
View details

James Harding

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Ming Yin

Assistant Professor

The Ohio State University Wexner Medical Center

UNITED STATES
View details

Yuanquan Yang

The Ohio State University Comprehensive Cancer Center

UNITED STATES
View details

Lipika Goyal

Director of Gastrointestinal Oncology

Stanford University

UNITED STATES
View details

Anne Noonan

Professor

The Ohio State University Comprehensive Cancer Center

UNITED STATES
View details

Andrés Cervantes

Professor of Medicine

University of Valencia

SPAIN
View details

Josep Tabernero

Associate Professor Faculty of Medicine

Universitat de Vic - Universitat Central de Catalunya

SPAIN
View details

Philippe L. Bedard

University Health Network

CANADA
View details

Petros Grivas

University of Washington

UNITED STATES
View details

Jin Won Kim

Professor

Seoul National University Hospital

SOUTH KOREA
View details

Michael J. Overman

-

UNITED STATES
View details

Razelle Kurzrock

-

UNITED STATES
View details

Elena Garralda

Director

-

SPAIN
View details

Funda Meric-Bernstam

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ingo Mellinghoff

Department Chair

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Teresa Macarulla

Head of Gastrointestinal and Endocrine Tumor Unit

Hospital Clínic de Barcelona

SPAIN
View details

Andrew Coveler

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Nick Pavlakis

Professor

University of Sydney

AUSTRALIA
View details

Christos Fountzilas

Associate Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Joshua K. Sabari

NYU Langone Health

UNITED STATES
View details

Do-Youn Oh

Professor

Seoul National University Hospital

SOUTH KOREA
View details

Mamta Parikh

Associate Professor

University of California Davis Comprehensive Cancer Center

UNITED STATES
View details